Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Figure 2 | Journal for ImmunoTherapy of Cancer

Figure 2

From: The IL-15 superagonist ALT-803 enhances anti-CD20 antibody-directed NK cell ADCC and in vivo clearance of B cell lymphomas

Figure 2

Alt-803+rituximab protects against lethal Daudi lymphoma challenge. Kaplan-Meir survival estimates of SCID mice injected iv with 1e7 Daudi lymphoma cells (day 0) and treated with vehicle (PBS). ALT-803 (day 15,18 0.05 mg/kg), rituximab (10 mg/kg day 15), or ALT-803+rituximab (day 15, 18). N = 7 mice per group. Significant (p < 0.05) survival improvement with ALT-803+rituximab compared to vehicle treatment group.

Back to article page